{"filing":{"accession_number":"0001654954-26-006557","cik":"0001131399","ticker":"GLAXF","company_name":"GSK plc","form":"6-K","filing_date":"2026-07-09","report_date":null,"primary_document":"a6975l.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131399/000165495426006557/a6975l.htm"},"events":[{"id":16788,"run_id":15017,"accession_number":"0001654954-26-006557","anchor_item_number":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"GSK announced the appointment of Roy Jakobs as a Non-Executive Director effective 13 July 2026. The disclosure details his background as CEO of Royal Philips, his independence status, compensation terms (£122,258 annual fee), and share ownership requirements. This is a clear executive appointment to the Board, material to investors assessing governance and leadership composition.","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-07-09","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":14988,"accession_number":"0001654954-26-006557","item_number":null,"item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"GSK announced the appointment of Roy Jakobs as a Non-Executive Director effective 13 July 2026. The disclosure details his background as CEO of Royal Philips, his independence status, compensation terms (£122,258 annual fee), and share ownership requirements. This is a clear executive appointment to the Board, material to investors assessing governance and leadership composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:29:48.062375+00:00","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-07-09"}]}